April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Patients with Neovascular AMD Treated with Ranibizumab Report Improvement in Function and Performing Everyday Activities in the MARINA Study
Author Affiliations & Notes
  • Rohit Varma
    Ophthalmology, USC, Doheny Eye Institute, Los Angeles, California
  • Neil Bressler
    Wilmer Eye Institute, Johns Hopkins University,, Baltimore, Maryland
  • Ivan J. Suner
    Retina Associates of Florida, Tampa, Florida
  • Paul P. Lee
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • James Ward
    Genentech, Inc., San Francisco, California
  • Chantal Dolan
    Genentech, Inc., San Francisco, California
  • Shoshana Colman
    Genentech, Inc., San Francisco, California
  • Footnotes
    Commercial Relationships  Rohit Varma, Allergan (F, C), Aquesys (F, C), Bausch and Lomb (C), Genentech (F, C), Laboratorios Sophia (C), Optovue (F), Pfizer (F, C); Neil Bressler, Genentech (F); Ivan J. Suner, Comentis (C), Eyetech (F, R), Genentech (F, C, R), Pfizer (F, C); Paul P. Lee, Alcon (C, R), Allergan (C, R), Genentech (F, C, R), Merck (F, I, R), Pfizer (C, R); James Ward, Genentech (C); Chantal Dolan, Genentech (C), SARCode Corporation (C); Shoshana Colman, Genentech (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 84. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Rohit Varma, Neil Bressler, Ivan J. Suner, Paul P. Lee, James Ward, Chantal Dolan, Shoshana Colman; Patients with Neovascular AMD Treated with Ranibizumab Report Improvement in Function and Performing Everyday Activities in the MARINA Study. Invest. Ophthalmol. Vis. Sci. 2011;52(14):84.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Previously published data suggest improved visual function in patients with neovascular AMD receiving ranibizumab compared to sham treatment as assessed by the NEI-VFQ 25 composite and subscale scores. However, these data do not provide information on the proportion of patients who report an improvement in their ability to perform everyday activities. In this analysis, we report on the magnitude of this treatment effect based on item-specific responses to near and distance visual function questions in the NEI VFQ-25 following 24 months of treatment with ranibizumab or sham.


In MARINA, subjects were randomized 1:1:1 to sham injection (n=238), or 0.3 mg (n=238) or 0.5 mg ranibizumab (n=240). Patient-reported level of difficulty on individual NEI VFQ-25 near and distance activities was compared at baseline and 24 months among subjects treated with sham or 0.5 mg ranibizumab. Improvement was defined as having less difficulty by 1 category or more on a 5-level difficulty scale (no difficulty at all, a little difficulty, moderate difficulty, extreme difficulty, stopped doing the activity).


Results are shown in Table 1. On average, twice as many patients reported an improvement in their ability to perform everyday near and distance tasks in the ranibizumab-treated group versus the sham group.


These data provide evidence that people with neovascular AMD treated with ranibizumab not only experience improved vision but also report improvement in the ability to function and perform everyday activities.  

Clinical Trial:

http://www.clinicaltrials.gov NCT00056836

Keywords: age-related macular degeneration • quality of life 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.